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Tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor (EGFR) are
the standard of care treatment in non-small cell lung cancer (NSCLC).TKIs are used first line
in EGFR mutation-positive NSCLC; erlotinib is the only TKI approved for subsequent lines
of treatment in EGFR wild-type NSCLC. As promising as TKIs are in helping patients avoid
some of the side effects of traditional cytotoxic chemotherapy, they do come with a variety
of side effects.This article will describe the most common adverse events associated with
the epidermal EGFR family of TKIs including diarrhea, rash, mucositis, and paronychia. The
objective of this paper is to provide simple guidelines to assist oncologists in managing
these common toxicities. As patient survival is often directly correlated with successful
therapeutic drug delivery, the management of TKI-induced adverse events ensures proper
treatment and may avoid discontinuation or reduction of the therapeutic.
Keywords: tyrosine kinase inhibitor, EGFR, adverse event management, diarrhea, rash, stomatitis/mucositis,
paronychia
INTRODUCTION
Tyrosine kinase inhibitors (TKI) are a relatively new class of tar-
geted therapeutics used to treat a range of diseases and disorders,
primarily cancers. The first TKIs, described in 1988, specifically
inhibited the epidermal growth factor receptor (EGFR) cascade
(1). This unique class of orally administered small molecule ther-
apeutics has found their way into the standard of care treatment
in almost all types of malignancy including non-small cell lung
cancer (NSCLC). Many new EGFR–TKIs will continue to emerge,
and the number of TKls in use will continue to expand.
Tyrosine kinase inhibitors may help patients avoid some of the
side effects of traditional cytotoxic chemotherapy, where toxicities
usually involve bone marrow involvement. However, as promis-
ing as the TKIs are, they do come with a variety of side effects.
These gastroenterologic side effects, such as diarrhea and mucosi-
tis, and cutaneous side effects, such as rash and paronychia, deserve
attention as successful management can extend the time that the
patient is on therapy. To date, there have been few clinical studies
conducted to study these side effects. The objective of this paper
is to provide simple guidelines to assist oncologists in manag-
ing these common toxicities. While the use of EGFR–TKIs can
also have more severe adverse events (SAE) including ocular dis-
orders, interstitial lung disease, or hepatotoxicity, these SAE are
uncommon and fall beyond the scope of this paper.
DIARRHEA
Diarrhea is one of the most frequent adverse events of EGFR–
TKI therapy. The gastrointestinal tract expresses EGFR on cells of
epithelial origin.
Abbreviations: BCCA, BC cancer agency; EGFR, epidermal growth factor receptor;
NCI, National Cancer Institute; NSCLC, non-small cell lung cancer; QOL, quality of
life; RCT, randomized clinical trial; SAE, severe adverse event; TKI, tyrosine kinase
inhibitor.
CAUSES AND INCIDENCE
Epidermal growth factor receptor–tyrosine kinase inhibitors
induced diarrhea is thought to result from excess chloride secretion
that causes a secretory form of diarrhea (2). Severe diarrhea can
result in fluid and electrolyte loss, which then can lead to dehydra-
tion, electrolyte imbalances, and renal insufficiency. Alterations in
gastrointestinal transit and digestion can lead to nutritional defi-
ciencies that can negatively impact the quality of life (QOL) of
patients (3).
The incidence of diarrhea with EGFR–TKI treatment in phase
III clinical trials ranges from 27 to 87% with up to 25% of patients
experiencing SAEs (Table 1).
GRADING AND ASSESSMENT OF DIARRHEA
The severity of diarrhea is graded using the National Cancer
Institute’s CTCAE (Table 2). These criteria (grades) do not pro-
vide a complete assessment, and additional information should
be obtained from the patient evaluation. It is important to rule
out other possible causes of diarrhea. These include medications
such as laxatives, stool softeners, antibiotics, or antacids; dietary
factors such as excess consumption of fiber or dairy products,
greasy foods; comorbid infections such as intestinal obstruction,
fecal impaction, and surgeries (short bowel or gastrectomy); or
radiation toxicity.
Laboratory investigations include a complete blood count and
differential to rule out neutropenia, blood tests to assess renal
function, and electrolyte abnormalities and a stool culture or
Clostridium difficile toxin screen to check for bacterial pathogens.
To rule out co-existing disorders such as bowel obstruction or per-
foration, abdominal radiography, endograph endoscopy, or biopsy
might need to be performed. Duration of diarrhea, stool charac-
teristics, and co-existing symptoms should also be obtained from
the patient (3, 4).
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MANAGEMENT RECOMMENDATIONS FOR DIARRHEA
Patients should be advised to immediately report any symptoms
of diarrhea, so they can be managed early and effectively. Patients
have to understand the importance of avoiding/preventing dose
reductions or discontinuation of EGFR–TKIs.
Dietary changes and over-the-counter anti-diarrheal medica-
tions can generally be used to manage EGFR–TKI induced diar-
rhea. This management is identical to that of chemotherapy-
induced diarrhea (3–5).
Patients who experience diarrhea should avoid greasy, spicy,
and fried foods as they can exacerbate the symptoms. Until symp-
toms start to resolve, patients can eat a diet of bananas, rice, apple
sauce, and toast (BRAT) and avoid foods that may increase abdom-
inal cramping and bloating such as Brussels sprouts, cabbage, and
broccoli. When symptoms start to improve, foods such as eggs,
pasta, and skinless chicken can be added. Patients should drink
3–4 l of fluid to prevent dehydration. Prolonged diarrhea may
cause diminished lactase activity resulting in lactose intolerance
Table 1 | Incidence of diarrhea with EGFR–TKIs in NSCLC clinical trials.
EGFR–TKI Description Grade (%)
All ≥3
Erlotinib 150 mg All studies (10–69) (0–17)
Phase III studies (40–68) (2–12)
Gefitinib 250 and 500 mg All studies (27–75) (0–25)
• 250 mg (27–58) (0–10)
• 500 mg (51–75) (5–25)
Phase III studies (27–69) (3–25)
• 250 mg (27–58) (3–10)
• 500 mg (51–69) (12–25)
Afatinib 40 and 50 mg All studies (67–100) (0–33)
• 40 mg (67–97) (0–7)
• 50 mg (87–100) (17–33)
Phase III studies
• 50 mg (87–17)
Dacomitinib 15, 30, and 45 mg All studies (phase II) (77–97) (0–15)
• 30 mg (77–0)
• 45 mg (81–97) (13–15)
Adapted from Hirsh (10).
thus milk products should be avoided for about a week following
diarrhea (3–5).
The pharmacologic management of diarrhea is generally lim-
ited to over-the-counter loperamide (Figure 1). After the first
diarrhea, patients should start 4 mg of loperamide followed by
2 mg after each loose stool or every 4 h to a maximum daily dose
of 20 mg. If symptoms persist for more than 24 h, the dose of
loperamide can be increased to 4 mg followed by 2 mg every 2 h.
If 12 h have passed without diarrhea, loperamide can be stopped
(3–6).
Epidermal growth factor receptor–tyrosine kinase inhibitors
cessation is required for grade 3 or 4 diarrhea and then restart
EGFR–TKI at a lower dose once the severe symptoms have sub-
sided. Use of octreotide is generally for chemotherapy-induced
diarrhea and there is no evidence to support its use in the
EGFR–TKI setting.
RASH
Cutaneous side effects of EGFT–TKIs can include skin rashes of
many different types and severity. The rash is very acne-like in
appearance, and is accurately described as a papulopustular erup-
tion. Other descriptions include the terms acneiform skin reaction,
acneiform rash, acneiform follicular rash, acne-like rash, mac-
ulopapular skin rash, and amonomorphic pustular lesions. The
EGFR–TKI induced rash most often appears on the face and chest,
but can be more widespread. The rash may be triggered by sun
exposure (7). Dry skin, pruritus, ocular, and hair changes are also
common.
CAUSES AND INCIDENCE
Epidermal growth factor receptor is expressed in the basal layer of
the epidermis, and its normal physiological roles include stim-
ulation of epidermal growth, inhibition of differentiation, and
acceleration of wound healing. As the name of this receptor is“epi-
dermal,” it is no surprise that inhibitor toxicity may include the
epidermis. Pathophysiological effects of EGFR inhibition include
impaired growth and migration of keratinocytes, and the expres-
sion of inflammatory chemokines by these cells, which results
in inflammatory cell recruitment (8). Not surprisingly, a histo-
logic analysis demonstrates a mixed inflammatory infiltrate in the
upper areas of the skin. This inflammation and subsequent cuta-
neous injury accounts for many of the symptoms observed in
patients being treated with this class of TKI, including tenderness,
papulopustules, and periungual inflammation (9).
Table 2 | US National Cancer Institute grading for diarrhea.
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
An increase of <4 stools over
baseline, per day
An increase of 4–6 stools over
baseline, per day
An increase of 7 or more stools
over baseline per day
Life-threatening consequences Death
Incontinence Urgent intervention indicated
Hospitalization indicated
Limits self-care activities of daily
living
Adapted from the Common Terminology Criteria for Adverse Events (15).
Frontiers in Oncology | Thoracic Oncology September 2014 | Volume 4 | Article 238 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Melosky and Hirsh Management of toxicities in metastatic NSCLC
FIGURE 1 | Management of diarrhea induced by chemotherapy or EGFR–TKIs. IV, intravenous, SC, subcutaneous, TID, three times daily. Adapted from
Hirsh (10).
There are several phases to the cutaneous manifestations.
In the first week of TKI treatment, patients often experi-
ence sensory disturbances, erythema, and edema. In the second
week of TKI treatment, patients experience papulopustular
eruptions, followed by crusting in week 4. In the 4–6 weeks
following, a background of erythema and dry skin can
be seen in areas previously affected by the papulopustular
eruption (8).
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Table 3 | Rate of grade 3 rash, Paronychia and Stomatitis/mucositis observed in trials.
Grade 3/4 adverse events EGFR–TKI and trial
Gefitinib Erlotinib Afatinib Afatinib
IPASS (3)
(N =607) (%)
EURTAC (4)
(N =84) (%)
LUX-Lung 3 (5)
(N =229) (%)
LUX-Lung 6 (6)
(N =239) (%)
Rash/acne 3.1 13 16.2 14.6
Stomatitis/mucositis 0.2 NR 8.7 5.4
Paronychia 0.3 NR 11.4 NR
NR: not reported.
Incidence of all grades of rash in phase 3 clinical trials varies
from 37 to 78% (10). Grade 3 rash ranges from 3.1 to 16.2%
depending on the trial (Table 3) (11–14).
MANAGEMENT RECOMMENDATIONS FOR SKIN RASH
Patient education is a very important aspect of management, and
several important points need to be communicated and empha-
sized. First of all, the rash is not contagious; the skin toxicity is not
infectious, but inflammatory. Secondly, this skin rash is not acne,
and so patients should be strongly discouraged from treating the
rash with over-the-counter acne medications, as acne medication
is very drying and will exacerbate the pruritus. Third, as dry skin is
almost universally experienced by patients taking this medication,
they should be instructed to use an alcohol-free emollient cream
applied twice daily, preferably to their entire body. Finally, since
sun exposure may aggravate the pruritus, patients are advised to
avoid sun exposure, and a broad spectrum sunscreen is strongly
recommended (9).
The specific treatment algorithms for rashes caused by EGFR
inhibitors vary widely throughout the different centers that use
these agents in their clinics. Nonetheless, some basic principles
may apply to all situations. Early treatment of rash can prevent
symptoms from becoming worse, so clinicians are advised to assess
patients weekly, and intervene when the first symptoms of rash
appear. Management strategies for EGFR–TKI induced rash are
shown in Table 4.
Mild reactions (NCI-CTC grade 1) (15) are gener-
ally localized with no associated physical symptoms. Treat-
ment options include topical low–medium potency corticos-
teroids. Other options include the addition of clindamycin
1% gel to hydrocortisone 1% and the use of oral semi-
synthetic tetracyclines (i.e., doxycycline or minocycline). The
EGFR inhibitor should be continued while the rash is being
treated.
Moderate reactions (NCI-CTC grade 2) (15) are more
severe and can include symptoms such as tenderness or itch-
ing. The recommended treatment is hydrocortisone 1 or 2.5%
cream± clindamycin 1% cream, as well as a 4-week course of
an oral tetracycline antibiotic, such as doxycycline 100 mg daily
or minocycline 100 mg twice daily. Minocyline can cause nausea
in a small percentage of patients, and reduction to 100 mg daily
may be better tolerated. As the rash from the EGFR–TKI may
wax and wane, the treatment may need to be repeated at several
intervals.
Table 4 | BCCA management guidelines for EGFR–TKI induced rash.
Grade Toxicity EGFR inhibitor
1 Macular or papular
eruption or erythema
with no associated
symptoms
Maintain dose level of TKI
Consider clindamycin 2% and
hydrocortisone 1% in a lotion to be
applied topically BID as needed
2 Macular or
papulopustular eruption
or erythema with pruritus
or other symptoms that
are tolerable or interfere
with daily life
Maintain dose level of TKI
Consider clindamycin 2% and
hydrocortisone 1% in a lotion to be
applied topically BID as needed
+minocycline 100 mg PO BID for
1–2 weeks or longer as needed
3 Severe, generalized
erythroderma, or
macular, popular or
vesicular eruption
Withhold EGFR TKI for 10–14 days
When improvement to grade 2 or
less, continue at 50% of original dose
If toxicities do not worsen, escalate
by 25% increments of original dose
until starting dose is reached
If no improvement, discontinue
Continue treatment with clindamycin
2% and hydrocortisone 1% in a lotion
to be applied topically BID as needed
+minocycline 100 mg PO BID for 1 to
2 weeks or longer as needed
4 Generalized exfoliative,
ulcerative, or blistering
skin toxicity
Discontinue treatment
Adapted from the management guidelines utilized in the BC Cancer Agency
(BCCA) Oncology Department.
Severe reactions (NCl-CTC grade 3) (15) are generalized with
major symptoms affecting activities of daily living and are intol-
erable to the patient. Though histological findings suggest that
the papulopustular eruption has an inflammatory component,
the use of topical oral corticosteroids is based on empirical data.
A temporary 7–10 days discontinuation of the TKI involved is
recommended, with subsequent reintroduction at a lower dose
according to the product monograph. Treatment with both a
steroid cream and oral tetracycline as per moderate rash is
encouraged during the interruption period. When treatment is
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reintroduced, dose escalation of the TKI being used is often
possible.
Some guidelines, including BC Cancer Agency guidelines,
include drug dose reduction to alleviate severe drug reactions.
While side effects of the TKIs are often unpleasant, effort must be
made to maintain patients on their cancer therapies. If a TKI is
administered in only one dose, for example, in the case of gefitinib
where only one dose exists, switching the patient to another TKI
that has more flexible dosing is strongly recommended.
Dry skin in the trunk and extremities is very common in
patients being treated with EGFR–TKIs. Fragrance free creams
and ointments are recommended over lotions, which may con-
tain alcohol. For scaling and hyperkeratosis, ammonium lactate
and urea-containing preparations are also useful, but they should
be used with care because of greater skin sensitivity in these
patients.
A scalp rash may be successfully treated with the basic princi-
ples above, however, a gel can be formulated as cream and lotion
treatment can be unappealing in the hair or hairline area of the
neck. Patients may often develop lesions and plaques on the scalp,
which can be treated with topical clindamycin 2% plus triamci-
nolone acetonide 0.1% in equal parts of propylene glycol and water
until resolution.
MUSOSITIS/STOMATITIS
In addition to diarrhea, patients taking EGFR–TKIs often experi-
ence other gastrointestinal side effects. Although used interchange-
ably, mucositis refers to inflammation of the gastrointestinal tract
while stomatitis refers to inflammation of the mouth (15, 16).
Symptoms can also include tingling in the mouth or on the tongue,
ulcers or cracks on the side of the mouth (B. Melosky, unpublished
observation). This side effect is rarely seen with the first genera-
tion TKIs, but is observed with the second generation TKIs. In
the original IPASS trial, 0.2% of patients treated with gefitinib
reported grade 3 mucositis/stomatitis (11), while 8.7% of patients
treated with afatinib in LUX-Lung 3 experienced grade 3 mucosi-
tis/stomatitis (Table 3) (13). As this is a new finding, the true
incidence of mucositis/stomatitis has not often been evaluated in
a trial setting.
MANAGEMENT RECOMMENDATIONS FOR MUCOSITIS/STOMATITIS
There have not been any randomized control trials to determine
the best ways to manage EGFR–TKI induced mucositis/stomatitis.
A careful examination of patients prior to treatment to determine
baseline oral health status and inflammation is recommended, as
well as observation during treatment (17). Patients are encouraged
to practice good oral hygiene including frequent brushing with a
soft brush, flossing, and rinsing with saline. Avoid commercial
mouthwashes as they often contain alcohol, which can exacerbate
the situation. As symptoms become more severe, oral care should
become more frequent (16).
The following strategies for treating stomatitis/mucositis are
recommended (Dr. Kim Papp, personal communication). The rec-
ommended treatment for grade 1 stomatitis/mucositis is kenalog
in Orabase®, applied two or three times a day. The recommended
treatment for grade 2 stomatitis/mucositis is kenalog in Orabase®,
with the addition of 250–350 mg of erythromycin a day. The
recommended treatment for grade 3 stomatitis/mucositis is clo-
betasol ointment instead of kenalog in Orabase®, with an increase
in erythromycin dose to 500 mg daily. EGFR–TKI is maintained
for grades 1 and 2, and temporarily discontinued for grade 3,
until the stomatitis/mucositis improves to grade 2, at which point
it is resumed at 50% of the original dose and then increased if
symptoms do not get worse.
PARONYCHIA
In addition to the skin rash,other cutaneous manifestations may be
observed in patients treated with EGFR–TKIs. Paronychia inflam-
mation or infections associated with the lateral nail folds of the toes
and fingers can become a concern after a longer period of treat-
ment. Although EGFR–TKI related nail changes are usually mild,
they can also be severe and symptomatic, especially with the newer
generation of TKIs (8, 18). Of note, paronychia is almost never seen
with first generation EGFR–TKIs, erlotinib, and gefitinib (Table 3).
MANAGEMENT RECOMMENDATIONS FOR PARONYCHIA
A challenge in managing paronychia is that there have not been
any randomized control trials testing out treatment/management
options. Patients are advised to use emollient lotions, to wear
gloves during chores or cleaning, and to avoid impacts on fingers
and toes.
Table 5 | Management guidelines for paronychia (Hirsh, personal
communication).
Grade Toxicity EGFR inhibitor
1 • Nail fold edema or
erythema
• Disruption of the cuticle
• Topical
antibiotics/antisepticsa
• Vinegar soaksb
• Topical ultrapotent steroids
(clobetasol priopionate)
applied twice daily
2 • Nail fold edema or
erythema with pain
• Associated with discharge
or nail plate separation
• Limiting instrumental
activities of daily living
• Same as in grade 1
• Silver nitrate application
weekly
3 • Limiting self-care activities
of daily living
Interrupt afatinib; refer to a
dermatologist and resume
afatinib at a reduced dose
(10 mg) if patient recovers to
grade ≤1
• Same as in grade 2
• Consider nail avulsion and
systematic antibioticsc
aExamples of topical antibiotics/antiseptics: clindamycin 1%, erythromycin 1%,
tetracycline 1%, or chloramphenicol 1%, iodine ointment.
bVinegar soaks consist of soaking fingers or toes in a solution of white vinegar or
water 1:1 for 15 min every day.
cSystemic antibiotics include tetracyclines and antimicrobials (erythromycin
should be avoided).
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The following strategies for treating the inflammation and
infection are recommended (Table 5, Dr. Hirsh). The recom-
mended treatment for grade 1 paronychia is topical antibiotics and
antiseptics including clindamycin 1%, erythromycin 1%, tetracy-
cline 1%, or chloramphenicol 1%, iodine ointment. Vinegar soaks,
whereby fingers or toes are soaked in a 1:1 solution of white vine-
gar and water for 15 min a day are recommended. In addition, oral
doxycycline may be effective along with a high potency corticos-
teroid such as clobetasol propionate applied to nail beds twice a
day. For more severe cases (grade 2), silver nitrate may be applied
weekly. Patients with splinter hemorrhages can be treated with
liquid bandage. In severe cases (grade 3), the EGFT–TKI should
be discontinued until symptoms improve. Additionally, intrale-
sional corticosteroid injections or removal of the nail plate may be
beneficial.
CONCLUSION
Tyrosine kinase inhibitors against the epidermal growth fac-
tor have become standard of care in cancers such as NSCLC.
Therapy with EGFR–TKIs has improved clinical outcomes, but
they are accompanied by a number of adverse events that can
be effectively managed, especially diarrhea, rash, mucositis, and
paronychia. Strategies for early and ongoing management of rash
and diarrhea are essential to patient compliance and treatment
outcome.
ACKNOWLEDGMENTS
The authors wish to thank Stavroula Kalantzis and Chrystal Palaty
for their assistance in the preparation of the manuscript.
REFERENCES
1. Yaish P, Gazit A, Gilon C, Levitzki A. Blocking of EGF-dependent cell pro-
liferation by EGF receptor kinase inhibitors. Science (1988) 242(4880):933–5.
doi:10.1126/science.3263702
2. Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical efficacy and toxic-
ity of anti-EGFR therapy in common cancers. J Oncol (2009) 567486(10):6.
doi:10.1155/2009/567486
3. Maroun JA, Anthony LB, Blais N, Burkes R, Dowden SD, Dranitsaris G, et al.
Prevention and management of chemotherapy-induced diarrhea in patients
with colorectal cancer: a consensus statement by the Canadian Working
Group on Chemotherapy-Induced Diarrhea. Curr Oncol (2007) 14(1):13–20.
doi:10.3747/co.2007.96
4. BC Cancer Agency (BCCA). BCCA Guidelines for Management of Chemotherapy-
Induced Diarrhea. (2004). Available from: http://www.bccancer.bc.ca/NR/
rdonlyres/4E7EF86A-EAA5-4F3C-B147-B2512799F6B3/7371/Guidelinesfor
ManagementofCID.pdf
5. Saltz LB. Understanding and managing chemotherapy-induced diarrhea. J Sup-
port Oncol (2003) 1(1):35–46.
6. Healthcare MC. Imodium Product Monograph. Guelph, ON: McNeil Consumer
Healthcare (2008).
7. Lacouture ME, Lai SE. The PRIDE (papulopustules and/or paronychia, regula-
tory abnormalities of hair growth, itching, and dryness due to epidermal growth
factor receptor inhibitors) syndrome. Br J Dermatol (2006) 155(4):852–4.
doi:10.1111/j.1365-2133.2006.07452.x
8. Lacouture ME, Melosky BL. Cutaneous reactions to anticancer agents targeting
the epidermal growth factor receptor: a dermatology-oncology perspective. Skin
Therapy Lett (2007) 12(6):1–5.
9. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev
Cancer (2006) 6(10):803–12. doi:10.1038/nrc1970
10. Hirsh V. Managing treatment-related adverse events associated with EGFR tyro-
sine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol (2011)
18(3):126–38. doi:10.3747/co.v18i3.877
11. Mok TSWY, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, et al.
Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med
(2009) 361(10):947–57. doi:10.1056/NEJMoa0810699
12. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al.
Erlotinib versus standard chemotherapy as first-line treatment for European
patients with advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol
(2012) 13(3):239–46. doi:10.1016/S1470-2045(11)70393-X
13. Yang JC, Hirsh V, Schuler M, Yamamoto N, O’Byrne KJ, Mok TS, et al. Symptom
control and quality of life in LUX-Lung 3: a phase III study of afatinib or cis-
platin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR
mutations. J Clin Oncol (2013) 31(27):3342–50. doi:10.1200/JCO.2012.46.1764
14. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cis-
platin plus gemcitabine for first-line treatment of Asian patients with advanced
non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an
open-label, randomised phase 3 trial. Lancet Oncol (2014) 15(2):213–22.
doi:10.1016/S1470-2045(13)70604-1
15. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03.
U.S. Department of Health and Human Services NIoH, National Cancer Insti-
tute (2010). Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_
2010-06-14_QuickReference_5x7.pdf
16. Brown CG, Yoder LH. Stomatitis: an overview: protecting the oral cavity during
cancer treatment. Am J Nurs (2002) 4:20–3. doi:10.1097/00000446-200204001-
00005
17. Lacouture ME, Anadkat MJ, Bensadoun R-J, Bryce J, Chan A, Epstein JB, et al.
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-
associated dermatologic toxicities. Support Care Cancer (2011) 19(8):1079–95.
doi:10.1007/s00520-011-1197-6
18. Melosky B. Supportive care treatments for toxicities of anti-EGFR and other
targeted agents. Curr Oncol (2012) 19(Suppl):1. doi:10.3747/co.19.1054
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 02 June 2014; accepted: 19 August 2014; published online: 16 September 2014.
Citation: Melosky B and Hirsh V (2014) Management of common toxicities in metasta-
tic NSCLC related to anti-lung cancer therapies with EGFR–TKIs. Front. Oncol. 4:238.
doi: 10.3389/fonc.2014.00238
This article was submitted to Thoracic Oncology, a section of the journal Frontiers in
Oncology.
Copyright © 2014 Melosky and Hirsh. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Oncology | Thoracic Oncology September 2014 | Volume 4 | Article 238 | 6
